Xenon Pharmaceuticals (NASDAQ: XENE) reported Q2 EPS of ($0.55), $0.07 worse than the analyst estimate of ($0.48). Revenue for the quarter came in at $500 thousand versus the consensus estimate of $4.18 million.

For earnings history and earnings-related data on Xenon Pharmaceuticals (XENE) click here.